Why Did Bill Ackman Buy Brookfield Stock?
Bill Ackman of Pershing Square Capital has made a number…
Sell
25
CNCR Quote, Financials, Valuation and Earnings
Last price:
$9.75
Seasonality move
:
2.31%
Day range:
$9.77 - $9.96
52-week range:
$7.88 - $16.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
907
Avg. volume:
1.9K
1-year change:
-29.93%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CNCR
Range Cancer Therapeutics ETF
|
$9.77 | -- | -- | -- | $0.00 | 0% | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
$15.76 | -- | -- | -- | $0.00 | 0% | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$21.22 | -- | -- | -- | $0.22 | 0% | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
$95.09 | -- | -- | -- | $0.04 | 0.34% | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
$40.16 | -- | -- | -- | $0.15 | 1.64% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CNCR
Range Cancer Therapeutics ETF
|
-- | 1.693 | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | 1.722 | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.000 | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | 1.371 | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | 0.808 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | -- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
Range Cancer Therapeutics ETF vs. Competitors
-
Which has Higher Returns CNCR or EKG?
First Trust Nasdaq Lux Digi Health Solutions ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat First Trust Nasdaq Lux Digi Health Solutions ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNCRRange Cancer Therapeutics ETF-- -- -- EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- -
What do Analysts Say About CNCR or EKG?
Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Lux Digi Health Solutions ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than First Trust Nasdaq Lux Digi Health Solutions ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than First Trust Nasdaq Lux Digi Health Solutions ETF.
Company Buy Ratings Hold Ratings Sell Ratings CNCRRange Cancer Therapeutics ETF0 0 0 EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF0 0 0 -
Is CNCR or EKG More Risky?
Range Cancer Therapeutics ETF has a beta of 1.110, which suggesting that the stock is 10.972% more volatile than S&P 500. In comparison First Trust Nasdaq Lux Digi Health Solutions ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CNCR or EKG?
Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Trust Nasdaq Lux Digi Health Solutions ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. First Trust Nasdaq Lux Digi Health Solutions ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNCR or EKG?
Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Lux Digi Health Solutions ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than First Trust Nasdaq Lux Digi Health Solutions ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while First Trust Nasdaq Lux Digi Health Solutions ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for First Trust Nasdaq Lux Digi Health Solutions ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNCRRange Cancer Therapeutics ETF-- -- -- -- EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- --
-
Which has Higher Returns CNCR or THNR?
Amplify Weight Loss Drug & Treatment ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat Amplify Weight Loss Drug & Treatment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNCRRange Cancer Therapeutics ETF-- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -
What do Analysts Say About CNCR or THNR?
Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Amplify Weight Loss Drug & Treatment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than Amplify Weight Loss Drug & Treatment ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than Amplify Weight Loss Drug & Treatment ETF.
Company Buy Ratings Hold Ratings Sell Ratings CNCRRange Cancer Therapeutics ETF0 0 0 THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 -
Is CNCR or THNR More Risky?
Range Cancer Therapeutics ETF has a beta of 1.110, which suggesting that the stock is 10.972% more volatile than S&P 500. In comparison Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CNCR or THNR?
Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amplify Weight Loss Drug & Treatment ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.22 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. Amplify Weight Loss Drug & Treatment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNCR or THNR?
Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than Amplify Weight Loss Drug & Treatment ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than Amplify Weight Loss Drug & Treatment ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while Amplify Weight Loss Drug & Treatment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for Amplify Weight Loss Drug & Treatment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNCRRange Cancer Therapeutics ETF-- -- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- --
-
Which has Higher Returns CNCR or XHS?
SPDR S&P Health Care Services ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNCRRange Cancer Therapeutics ETF-- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About CNCR or XHS?
Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than SPDR S&P Health Care Services ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings CNCRRange Cancer Therapeutics ETF0 0 0 XHSSPDR S&P Health Care Services ETF0 0 0 -
Is CNCR or XHS More Risky?
Range Cancer Therapeutics ETF has a beta of 1.110, which suggesting that the stock is 10.972% more volatile than S&P 500. In comparison SPDR S&P Health Care Services ETF has a beta of 1.045, suggesting its more volatile than the S&P 500 by 4.477%.
-
Which is a Better Dividend Stock CNCR or XHS?
Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SPDR S&P Health Care Services ETF offers a yield of 0.34% to investors and pays a quarterly dividend of $0.04 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNCR or XHS?
Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Services ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than SPDR S&P Health Care Services ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNCRRange Cancer Therapeutics ETF-- -- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- --
-
Which has Higher Returns CNCR or XPH?
SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNCRRange Cancer Therapeutics ETF-- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About CNCR or XPH?
Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than SPDR S&P Pharmaceuticals ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings CNCRRange Cancer Therapeutics ETF0 0 0 XPHSPDR S&P Pharmaceuticals ETF0 0 0 -
Is CNCR or XPH More Risky?
Range Cancer Therapeutics ETF has a beta of 1.110, which suggesting that the stock is 10.972% more volatile than S&P 500. In comparison SPDR S&P Pharmaceuticals ETF has a beta of 0.715, suggesting its less volatile than the S&P 500 by 28.453%.
-
Which is a Better Dividend Stock CNCR or XPH?
Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SPDR S&P Pharmaceuticals ETF offers a yield of 1.64% to investors and pays a quarterly dividend of $0.15 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNCR or XPH?
Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNCRRange Cancer Therapeutics ETF-- -- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Is Netflix a Must-own Stock?
The early months of 2025 have been very hard on…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 26
Saia [SAIA] is down 30.77% over the past day.
Sell
48
APPF alert for Apr 26
AppFolio [APPF] is down 18.16% over the past day.
Sell
15
KNSL alert for Apr 26
Kinsale Capital Group [KNSL] is down 16.33% over the past day.
